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Abstract 
Al Kamal, Nasrah. M.S. Program of Microbiology and Immunology, Wright 
State University, 2015.Immunotherapy for Human Breast Cancer.  
The study focuses on the methodologies that are used in breast cancer therapy. The 
review finds major evolutions of these methods and the influence they have made on the 
increased survival rates in cancer patients. There is also a projection of the processes that are 
involved in the therapy practices and the way the protocols have been improved over time. The 
various stages of cancer treatment project the various aspects of better performance articulations 
in the therapy sector. There is also reference to what is supposed to be done to reduce the 
limitations in cancer therapy contingencies.  
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Introduction 
 The Immune system is very critical in suppression of cancer development. However, 
cancer cells have evolved mechanisms to destruct by these immune cells. Immune cells are 
actively involved in suppression of cancer cells in early stages of development, but with time the 
cancer cells alter the immune cells to the extent that they begin promoting tumor progression 
through the provision of conditions that select tumor cells able to grow in the host and 
facilitating their growth. In most cases the tumors are contained by the active immune system to 
allow active involvement of innate and adaptive immune responses involving the macrophage 
system. However, the cancer cells bypass immune cells by modifying the basic cell systems such 
as apoptosis and tumor suppressor gene mutations, leading to a shift in the expression of the 
cancers (Arteaga, 1992). 
Cancers develop more easily with advance age in most cases, and breast cancer is no 
exception. The continued shortening of Telomeres in the chromosomes can lead to deletions in 
tumor suppressor genes, apoptosis mediating genes and proto-oncogene modification to 
oncogenes. These factors in an immunocompromised individual usually allow the growth and 
survival of the cancer cells. Cancers can be metastatic or non-metastatic in an individual. 
Metastatic cancers are usually disastrous and difficult to treat because they spread to various 
body tissues and organs and resist chemotherapy and other forms of treatment become challenge 
(Moen & Stuhr, 2015).  
 Breast cancer is among the most studied forms of cancer. It is among the cancer 
treatments that have received immune-based treatment strategies in the biomedical science field. 
Currently, this form of cancer is the mostly commonly diagnosed cancer among women in the 
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world, forming 12% of all the cancer diagnoses. (Vetvicka et al., 1999). Therefore, Breast 
Cancer has been declared by the World Health Organization as the second leading cause of 
deaths associated with cancer in women, with 520,000 deaths out of the approximately 
diagnosed 1.8 million women in U.S in 2012. The data is an equivalent of about 1out of 8 
woman at risk as compared with the exposure risk of 1 man per 1000. Higher risks of breast 
cancer are usually associated with genetic mutations that can be passed to on the hereditary 
generations. These mutated genes such as BRCA1 and BRCA2 may invariably be expressed with 
time in an individual to bring about the cancer and they are including the tumor susceptible 
genes. (Patt et al., 1993) 
 The 5-10 % risk of developing breast cancer if it inherited predisposition chance which 
is direct contrast to other kind of cancer form acquired by other means that accounts to less than 
1% in the general population. Other factors that culminate the development of breast cancer 
include but they not limited to hormonal therapies which both estrogen and progestin, heavy 
alcohol intake, reduced physical activity, high breast tissue density and obesity. In general, 
mutations in BRCA1 and BRCA2 are the leading cause of breast cancer, accounting for a 55-
65% of all breast cancers (Stähli et al., 1985).  
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Figure 1: Female breast cancer incidence rates, by age group in Ontario between the year 
1981 – 2009, (Adapted from qap.sdsu.edu). 
This figure shows that the older people were more susceptible to breast cancer than younger 
people.  
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Figure 2: Incidence and mortality rates of breast cancer in USA between the years 1971 
and 2009, (Adopted from qap.sdsu.edu). 
The figure 2 shows the incidence rates of breast cancer in USA between the years 1971 and 2009 
was higher than mortality rates. 
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Incident source: Combined data from the National Program of Cancer Registries as 
submitted to CDC and from the Surveillance, Epidemiology and End Results Program as 
Submitted to the National Cancer Institute in November 2014. 
Female Breast Cancer Incidence Rates by Race and Ethnicity, U.S., 1999-2012 
 
Figure 3: Female Breast Cancer Incidence Rates by Race and Ethnicity, U.S., 1999-2012, 
adapted from (kff.org). 
Death rate was also analysed with a report obtained, as from 1999-2012, variations in 
death rates were evident, depending on race and ethinicity. Black women showed elevated death 
rate compared to other groups. (Zhou et al., 2007) 
Mortality source; U.S. Mortality files, National center for Health Statistics, CDC 
Female  Breast Cancer 
Death Rates by Race and Ethinicity, U.S, 1999-2013 
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Breast cancer has had misconceptions about race or ethinicity relationships, below is an 
analysis of cancer victims across all races. It shows the number of women out of 100,000 got 
infected with breast cancer each year during the years 1999-2012. Figure 8 shows high rate of 
white women infected by breast cancer as at 2012 (Hilgers et al., 1985).  
 
 
 
 
 
Figure 4: Death Rates by Race and Ethnicity, U.S, 1999-2013, (adapted from kff.org). 
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Breast cancer treatment 
 Just like other cancer therapies, the main aims of treating breast cancer are to completely 
eliminate the cancer and to prevent recrudescence of the cancer in the individual at any given 
point in life. In most cases, cancer therapists evaluate the type of treatment before actual 
administration. The type of breast cancer an individual suffers from, the extent of spread of the 
tumor and its size, age and presence or absence of receptors for HER2 protein, progesterone as 
well as estrogen. ('Breast Cancer Research and Treatment', 2003). 
Treatment options include surgery to remove the affected breast, or lumpectomy which 
involves removal of the affected tissues only, leaving the breast intact. Radiation therapy, a 
commonly used form of treatment, uses high frequency waves to kill the cancer cells. Other 
therapies such as chemotherapy and hormone therapy are currently receiving attention by 
scientists since they target treatment at genetic levels of the individuals. For instance, hormone 
therapy involving the targeting of the genes responsible for the production of estrogen that may 
promote feeder hormone for breast cancer cells. Such drugs include tamoxifen used by 
premenopausal and postmenopausal women and anastrozole, exemestane and letrozole that are 
used for postmenopausal women. In some instances, there may be an option of combining the 
therapies to offer maximum achieved therapy. Targeted hormone and chemotherapy may be 
supplemented with irradiation of the cancer cells so as to completely kill them (Bunnell, 2000). 
However, this is require higher levels of expertise to avoid life threatening or metastasis 
encouragement (Poulin et al., 1988). 
Immunotherapy is the most recent therapy that is being to treatment of Breast Cancer and 
has advantages over the forms of treatment such as chemotherapy and targeted therapies since it 
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is highly effective and less traumatizing. Immunotherapy conventionally have very few side 
effects and thus can be administered to an individual for much longer periods of time with little 
or no toxicity. This kind of therapy has also received minimal resistance by most patients and 
target specific cancer antigens by using specific immune cells such as macrophages. For 
instance, the use of immune check point inhibitors such as programmed cell death protein 1 have 
led to an overall extension of survival for patients with metastatic cancers as well as breast 
cancer (Rocha et al., 2012). 
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Treatment approaches for each therapy in breast cancer. 
Type of immunotherapy  Drugs/approach used 
Monoclonal antibodies Trastuzumab 
Ado-trastuzumab 
Therapeutic vaccines NeuVax 
GVAX 
 
Checkpoint inhibitors Ipilimumab 
Pembrolizumab 
 
Adoptive T cell therapy Chimeric Antigen Receptors(CARs) 
 
Table 1: Treatment approaches for each therapy in breast cancer, (Adapted from National 
Cancer Institute, 2015). 
 
 
 
 
   
 
  
10 
 
Hypothesis 
 This new breast cancers therapy is designed to elicit immune responses that target the 
cancer associated antigens to destroy the marked cancer cells. This study addresses the role of 
macrophages in breast cancer development and its sustenance. 
 
 
Aims of the study 
 To determine the effectiveness of therapeutic vaccines such as GVAX and 
NeuVax in breast cancer treatment 
 To evaluate the effectiveness of checkpoint inhibitors and their contribution to 
breast cancer therapy 
 To establish the effectiveness of adaptive T-Cell therapy in breast cancer 
treatment 
 To evaluate the role of genetically engineered monoclonal antibodies in targeting 
breast cancer antigens 
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Background 
Macrophages 
  Macrophages are a core participant in general cellular immunity of an individual 
following an infection. They have a very important role in maintaining the host defense system 
involving both the acquired and innate immunity (Djawari et al., 1978). These cells have their 
origin in the bone marrow bound from pro-monocytes and monocytes that are then released into 
the blood stream. Macrophages are characterized for their ability to shift their roles in response 
to various microenvironments  
Development and differentiation of the Macrophage system. 
 Macrophages also develop in line with monocytes that form the Mononuclear Phagocyte 
System (MPS). They have a common precursor called the myeloid progenitor that also produces 
granulocytes. These myeloid progenitor cells give rise to monoblasts that produce promonocytes. 
These promonocytes develop to form monocytes which further move to tissues and blood in the 
body. Colony Stimulating factor 1 (CSF-1), FMS-like Tyrosine Kinase 3 Ligand and 
Granulocyte Macrophage Colony stimulating factor (GM-CSF) stimulate the myeloid precursor 
cells to initiate the macrophage cell development. CSF-1 is an essential component in the overall 
production of tissue macrophages and normal cell development. The GM-CSF is actively 
involved in stimulating the differentiation of the bone marrow as well as the monocyte 
population in response to Antigen Presenting Cell’s activity. The production of macrophages 
largely depends on the presence of Interleukin 1 and 3 target with CSF-1, GM-CSF and 
Interferon gamma (Djawari et al., 1978). 
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Macrophage polarization 
 Macrophages can be broadly classified into two basic categories: Type I and Type II 
macrophages. Type I and Type II cells are defined as M1 and M2, respectively, depending on the 
receptors, functions, and their production cytokine. Pro-inflammatory macrophages are produced 
by M0 cells through activating of Interferon gamma and a set of lipopolysaccharides. (Pro-
inflammatory macrophages are also termed M1 macrophages). The anti-inflammatory 
Macrophages (M2) usually develop following an exposure to Interleukin-1, Interleukin-10 and 
Interleukin-13. Interferon gamma as well as the Lipopolysaccharides activate the anti-
inflammatory macrophage phenotype lineage. When the anti-inflammatory macrophages are 
associated with tumor suppression, they are regarded as Tumor-Associated macrophages 
(TAMs). To a larger extent, the M1 cells are characterized by their anti-tumor activity with the 
ability to initiate the destruction of tissues. On the other hand, the M2 line of macrophages are 
associated with the initiation of repair of the affected tissues, remodeling as well as promoting 
the tumor cells. However, the production of TAMs lead to the reduction of anti-tumor events as 
well as a rise in the production of the mediators for angiogenesis (Sapra et al., 2005). 
Figure 5 illustrates the activation of macrophages, the (M1) pro-inflammatory and (M2) 
anti-inflammatory, as well as their effects on the growth of tumors. TAM (M2 macrophage) 
predominate in tumor responses. Cells with the M1 phenotype contain antitumor activity and 
initiate the destruction of tissue. The M2 phenotype, on the other hand, develops after IL-4 
activation, initiating tissue repair, remodeling and promotion of tumor growth. Most TAMs are 
M2 cells, which result from multiple signals produced in the tumor microenvironment. The 
alternate activation of TAMs results in a reduction in the antitumor activities and increased 
production of angiogenic mediators. Inhibition of the M2 phenotype and the induction of M1 
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signals can reestablish TAMs as an effective therapy in reducing tumor size (Leyva-Illades et al., 
2012). 
 
 
 
Figure 5: The Impact of Macrophages on the Growth of Tumor and their Differential 
Activation. M1 (pro-inflammatory), M2 (anti-inflammatory) (adapted from Leyva-Illades 
et al., 2012). 
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Role of Tumor Infiltrating Lymphocytes in Breast Cancer 
 Tumor Infiltrating Lymphocytes (TILs) has been observed mostly in a number of 
presented breast cancer cases. The developing forms of the cancers that have a negative status 
enlargement of the axillary lymph nodes characteristic a relatively small size of tumor and 
usually low grade ones are studied by use of the Tumor infiltrating lymphocytes. Tumor 
Infiltrating lymphocytes have a negative correlation with the age of a patient and their count too 
is positively associated with the survival span of the affected patients with the estrogen receptors. 
TILs are the predictive and potential prognostic markers in breast cancer. When a local relatively 
developed breast cancer is treated with neoadjuvant chemotherapy, any occurrence of tumor 
infiltrates of lymphocytes is an evident predictor of the response (Criscitiello et al., 2014). 
Macrophages in Cancer Development 
 Macrophages and their monocytes are converted to tumor associated macrophages 
(TAMs) when there is a tumor in the body of an individual. These cells are usually attracted 
towards the tumor cells when there is sufficient signaling as they move past the blood to the 
tissues. The attraction is facilitated by a cascade of events that are mediated by chemokine 
production. The most common chemokines include CCL2, and CCL5 (RANTES). Of the two, 
CCL2 is a chemoattractant that mediates the attraction of monocytes towards the point of tumor 
location. The Chemokine is produced by malignant breast cells which facilitates the movement 
of monocytes and macrophages as the immediate responders to kill the mutated cells. The 
absence of chemokine CCL2 does not regulate the number of macrophages that can be found in a 
malignant cell. Instead this may directly affect the number of monocytes moving towards this 
tissue. When the levels of CCL2 are high, the infiltrating macrophage number increasingly 
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becomes so bulk and this may mediate the destruction of a tumor at its early levels of 
development. The Macrophages initially show a high potential of clearing the cancerous cells 
with the production of apoptotic factors and the secretion of extracts of highly reactive oxygen 
species such as Nitric Oxide (NO). CCL5 is also produced by Breast Tumor cells alongside 
Naïve T cells. CCLs in turn stimulates the monocyte infiltration and expression of CCL2, CCL3, 
CCL4 and IL-8. The chemokines further facilitate the movement of myeloid cells and other 
monocytes and macrophages to the site of the tumor to fight the inflammation (Venglinskaya & 
Shubich, 1974). 
 Macrophages and monocytes are also recruited to tumor sites by cytokines. The Tumor 
cells produce Colony Stimulating Factor 1. Colony Stimulating Factor on its own facilitates the 
survival, growth, proliferation and differentiation of the tumor cells and macrophages. 
Monocytes and macrophages are also characterized the production of cytokines. Therefore, this 
stream of independent production of Colony Stimulating Factor allows for a competing colony of 
proliferating tumor cells. At some point, the macrophages facilitate the production of cytokines 
that stimulate of the growth of the tumor colonies as a well as encourage the process of 
angiogenesis (Venglinskaya & Shubich, 1975). 
The Angiogenic Growth Factor, Vascular Endothelial Growth Factor (VEGF), is 
associated with the presence of the macrophages and monocytes in tumor cells. This factor also 
plays the role of a chemoattractant by attracting free circulating macrophages that can destroy the 
tumor cells before macrophages get overwhelmed and mutated. The attraction occurs by the 
activation of tyrosine kinase receptors in the macrophages. Similarly, Endothelins, ET-1, ET-2 
and ET-3 are also associated with macrophages. These endothelins usually bind to peptides that 
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further bind to G-protein linked transmembrane receptors. In face of tumors, endothelins are 
produced in presence of macrophages. These endothelins in turn have a duty in stimulating 
tumor development and facilitating apoptotic inhibition, enhancing metastasis, angiogenesis and 
mutagenesis. Therefore the macrophage cell-lines may fall as victims of mutation in presence of 
the endothelins thus allowing for development of the tumor cells (Schumacher et al., 1993). 
Role of tumor Associated Macrophages in Tumor sustenance  
 Normally, TAMs are associated with cytotoxic activity on tumor cells and direct 
recruitment of immune response in tumor clearance. The M2 TAMs may stimulate the growth of 
tumors, development of new blood vessels (Angiogenesis) and metastasis.M2 TAMs are 
associated with the stimulation of tumor growth and development. Facilitates of the production 
of cytokines that stimulate the proliferation of malignant cells through direct recruitment of 
endothelial cell proliferation as well as angiogenesis. The M2 TAMs also produce Tumor 
Growth Factor-Beta (TGF-β) which is an immunosuppressive component that inhibits the anti-
tumor responses of the Cytotoxic T-Cells .Tumor Associated Macrophages also facilitate the 
proteolytic remodeling of the extracellular matrix that is essential in various points during the 
multistage development of the tumors (Schneble et al., 2014) 
Macrophage contribution in Angiogenesis 
Angiogenesis is developing new blood vessel supply from the existing ones. The ability 
of macrophages to secrete a wide range of chemokines, growth factors, and a varied range of 
enzymes allows them to facilitate the angiogenesis process which results to the establishment of 
new and fully independent blood vessels from the wild ones. Three steps are associated with 
angiogenesis mediated by Macrophages. TAMs produce endothelins, chemokines, Interleukin-
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17, Interleukin-23, TGF-β and VEGFs to promote angiogenesis. The initial step is the initiation 
of endothelial cell growth and further proliferation of breast tissue cells. (Fortier et al., 1994). 
This is followed by a coordinated production of metalloproteases that degrade basement 
membranes and the vessels that supply them. This process of degradation involves mostly 
proteases called Metall. This protease activity allows an easy sprouting and migration of the host 
endothelial cells into the developing malignant cells of the breast. Finally, there is an unregulated 
process of new tube formation similar to those of embryonic origin. This tube forms a new blood 
vessel that is supplied with numerous capillaries and venules. The blood vessel undergoes further 
stabilization with the attachment of mural cells and to collagen fibers to attain maturity. In turn, 
the tumor cells become independent and continue multiplying that cannot be recognized as non-
self by the immune system (Venglinskaya & Shubich, 1975). 
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Figure 6: Adaptive T Cell patient monitoring (Adapted from wikipedia, 2015). 
 
 
 
 
 
 
 
   
 
  
19 
 
 
 
Figure 7: Understanding the adaptive T cell (Adapted from Eggermont et al., 2014). 
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Literature review 
 Nearly all the currently available therapeutic approaches in Breast cancer treatment and 
management focus on the improvement of the activity of immune cells including macrophages 
and monocytes. The entire research work that has been done over decades has been 
supplemented with knowledge on the production of chemokines, cytokines and the activity of the 
biomolecules that facilitate tumor cell multiplication and angiogenesis. T cells and macrophages 
have been studied with their potential targets understood, a factor that offers information on the 
establishment of therapeutic measures (Segal et al., 2013). 
Adenocarcinoma,a cancerous tumor that can affect various body organs including human 
breast, has clinically shown great host resistance factors. Human breast cancer develops from 
breast tissues. Its signs can vary depending on the victim, but the common ones include; a lamp 
in the beast, a unique fluid discharge from the nipple, for instance a milky discharge when a 
woman is not breastfeeding, enlargement of pores around the breast skin, change in breast or 
nipple appearance, for instance, dimpling on the breast, shrinkage of the breast, and the nipple 
might become slightly inverted (Murray et al., 1994).  
Monoclonal antibodies (MAbs) can be used for cancer treatment. It is possible to produce 
these antibodies in the laboratory, by injecting an animal, for example mice or horse with an 
antigen from an affected human cell. The antibody producing cells are collected from the animal 
and fused with a cancerous B cell, this process will lead to production of hybridoma cells. 
Genetic engineering process can then be used to humanize the hybridoma cells. Cancer vaccines 
are not designed to prevent malignancy but rather to treat cancer that has already developed (Liu, 
2014). 
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Breast cancer, just like other forms of cancer, can be diagnosed at its very early stages of 
development and the correct therapy initiated to destroy the cancerous cells. The basic form of 
offering therapy begins with carrying out surgery, belong by other forms of treatment such as 
hormonal therapy, drug chemotherapy and irradiation of the cells. Breast cancer immunotherapy 
has previously been focused with the potential of fast improvement of the treatment plans in the 
host individuals. Immunotherapy in breast cancer treatment has been associated with the low or 
no side effects that are experienced, less chances of developing immune resistance and the ability 
of the therapy to be offered to patients for quite longer periods of time in association with other 
forms of drugs (Davies, 2009). 
 A number of immunotherapy approaches have been developed to counter the severity of 
progression and development of breast cancers. Such therapies include: use of therapeutic 
vaccines such as Nelipepimut-S (Neuvax/ E75), GVAX and trastuzumab conjugated to an 
adjuvant, use of checkpoint inhibitors, adoptive T cell Therapy and genetically engineered 
monoclonal antibodies designed to target antigens produced by breast tumor cells (Schneble et 
al., 2014). The stage of the cancer, type and the age of the patient form the basic factors to 
consider when carrying out a therapy.  Any case diagnosed early enough is an advantage to the 
patient (King, 2004). 
Advances are being made in research to offer the best in breast cancer therapy. For 
instance, Ming Li (A grantee at Memorial Sloan Kettering Cancer Center) has over time studied 
the activated pathways in cancer associated cells that mark beta-blockers. Beta blockers are 
prescribed to high blood pressure patients and this has to facilitate longer survival to the breast 
cancer patients. In his study, T cells are targeted if they can respond to beta-blockers thus to a 
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greater extent opening up more targets for the anti-cancer drugs. Other studies are based on 
inhibition of the signaling pathways that aid in the maintenance of tumor survival that will lead 
to the production of specific antibodies that can aid in breast cancer therapy (Davies, 2009). 
Therapeutic vaccines in the treatment of cancer 
 Immunoediting has proved to suppress growth of tumors through attacking and 
subsequent destroying of tumor cells. These modalities in immunotherapy have made a new 
perception of therapeutic clinical trials that potentially improve and encourage survival to some 
level (Patients with hormone-refractory, metastatic prostate cancer treated with GVAX cancer 
vaccine have demonstrated encouraging survival outcomes, 2007). 
Cancer Immunoediting 
 The immune system changes the conformation of a tumor in a process called editing in a 
very selective manner. Immunoediting involves pure selection against the tumor variants which 
do not express or poorly express the specific antigens that are recognized by the immune system. 
This is done through a cascade of events that eliminate those epitopes, which in some way do not 
express the antigenic epitope thus all those epitopes that are negative do not become visible to 
the Cytotoxic T-Lymphocytes. However, over time there has been a problem that is attributed to 
lack of complete clearance of the tumor cells by the Cytotoxic T-Lymphocytes. This has been 
attributed to the fact that a number of antigens expressed by tumor cells are directly subjected to 
simple by the immune systems and thus the Cytotoxic T-Lymphocytes associated are destroyed 
by the thymus gland in a process referred to as central tolerance ('Cancer vaccine-GVAX: 
potential in NSCLC', 2004). 
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Patterns of Cancer Vaccine Development 
 The application and the use of therapeutic vaccines has been complemented by an 
understanding of the antigens being produced by the breast tumor cell that are specific to 
infiltrating T cells of the patient’s immune systems. Previously, patients have been treated with 
vaccines that contained about 8 to 10 amino acid long Cytotoxic T lymphocyte peptides that 
were obtained from the understood tumor antigen sequences. This was attributed to the fact that 
CD8+ T cells are involved in the active process of attacking and lysing the invading cells 
including tumor. However, this trial never demonstrate the clearance of tumor cells as the 
specific anti-tumor cells in the CD8+ colony proved to be sub-optimal and had limited life spans.  
The patients in the clinical trials were those with heavy tumors with high levels of mutant 
antigen production and high suppression levels ('Cancer vaccine-GVAX/leuprorelin/nadroparin 
calcium', 2009).  
  A vaccine called GVAX was among the early anti-tumor vaccines developed in breast 
cancer treatment. This vaccine used irradiations to the breast cells that were producing GM-CSF 
that did not show any success in meeting the target. Current studies are focusing on priming the 
naïve T cells to play the role of effectors in clearance of cancers. The US FDA has approved the 
use of a vaccine that has been designed to stimulate of immune responses to breast cancer cells 
in a more personalized form (Singh & Gulley, 2014).  
On the other hand, recombinant pox viruses have been used in the delivery of vaccines. 
These viruses are used as vectors to transmit the desired therapeutic agent or cause recombinant 
mutations in the tumor cells to cause normal sequence alignments of the genes that code for the 
tumor cells. The use of recombinant viruses that encode for PANVAC and PROSTVAC have 
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been an active therapy in patients with different forms of cancer including prostate and breast 
cancer. The use of viruses in drug delivery includes both uses of in vitro methods to integrate the 
active molecules of the therapeutic agents into the virus’ genome (Sousa-Canavez et al., 2008).  
 The sequence of the virus must be understood to correlate with that of the gene 
responsible for a given tumor and due to this, the cell is targeted to modify the mutated sequence 
in an effort to change the expression of the contributing molecules for cancer development. 
Results from studies involving the use of pox viruses as chemotherapeutic agents have proved 
that the slow and progressive activation of the immune system on infusion of a vaccine has 
benefited most patients with breast cancer. This kind of therapy is highly effective to patients 
with metastatic forms of the cancer (Stein et al., 2004). 
Current trends in cancer vaccine therapy 
 More advances are being made towards establishing fully active chemotherapeutic agents 
that can aid in clearing and preventing growth of tumors even in predisposition to the causative 
agents. Chemotherapeutic programs aim at the generation of specific responses that mediate 
cellular immune responses to kill any abnormal cell or tissue. This aims at making a change in 
reversal of the immunosuppressive systems and in a way through the stimulation of the immune 
system and its effectors. To some other level, it is to be understood that the chemotherapeutic 
agents that are being administered usually after vaccines have showed to take advantage of any 
hyper-response by the immune system and lead to more desirable outcomes in the treatment 
strategy (Limacher et al., 2013). 
The use of vaccination and subsequent chemotherapy follow ups confirm a better 
response in terms of low tumor recurrence as compared to the previous patterns of reappearance 
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of the tumors. The survival rate is also increased in such patients as compared to those that 
receive chemotherapy alone. Another form of current technology in vaccines is limited to the use 
of monoclonal antibodies that are modified to specifically act as antagonist’s bodies that act to 
inhibit receptors of the antigens or as agonists that target the potential immune enhancing 
receptors thus the overall antitumor immunity is achieved. Vaccines are currently being 
combined with monoclonal antibodies especially the immunostimulatory antibodies that are 
based on the initiation of immune response to the tumors as well as the active inducing of 
anticancer responses with specific cancer responses since the antigens that are produced are 
easily marked by the modified immune systems with active maintenance of the system by use of 
memory cells (Madan et al., 2011). 
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The current survival rate is 90% up from 63% as per 1960s. 
When Cancers rapid a protein receptor is called HER2.theis kind of cancer can be treated 
with the use of targeted therapies. For example, pertuzumab and trastuzumab and in case of 
advanced cancer lapatinid (tykerb) or ado- trastuzumab  emetansine (Kadcyla), The newest 
treatment choices are pertuzumab as well as ado-trastuzumab emtansine. The Pertuzumab was  
the first-line treatment of HER2+ metastatic breast cancer in conjunction with trastuzumab or 
(Herceptin) and the chemotherapy docettaxel (Taxotere). Ado-trastuzumab emetansine or 
(kadcyla ) which is a HER2 targeted antibody with chemotherapy attached by linker, and is 
premeditated to deliver chemotherapy straight to the tumor through HER2-positive ('The GVAX 
cancer vaccine plus ipilimumab is active in the treatment of patients with advanced prostate 
cancer,', 2007).  
GVAX can be best examined in patients with stage 4 breast cancer that does not express 
HER2. It is a cancer vaccine that is obtained from cancer cell that have been irradiated and 
engineered to express the immune molecules GM- CSF, these genetically modified tumor cells 
can help the immune system to effectively respond to cancer cells. Cyclophosphamide together 
with and tratuzumabs can elevate the number of immune cells hence, boosting the immune 
system (Davies, 2009). 
Neuvax is made up of peptide, obtained from combination of HER2 protein and GM-
CSF. Prescription for its dosage is ones, each month, for a period of six months. Neuvax vaccine 
is aimed at preventing or controlling the regeneration of cancer cells that are known to course 
breast cancer (Davies, 2009). Below is a cancer vaccine trial table presented at American society 
of Clinical Oncology Breast Cancer Symposium in September 2014. 
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Clinical trials. Gov 
Identifier 
 
Type of vaccine Patients 
with; 
Time frame status 
NCT00524277 
 
 
 
 
Her2- derived HLA 
class 1 peptide(GP2) 
with GM- CSF 
  
 
Her2+ 
breast 
cancer 
 Five years 
 
Active, 
preventing 
 
NCT00854789 Her2- HLA class 1 
peptide(E75) with 
GM-CSF 
Her2+ 
breast 
Cancer 
vaccine to induce an 
in vivo peptide-
specific immune 
response 
Period needed to 
determine maximum 
tolerated and 
optimal biologic 
doses (30 days after 
each monthly dose.  
Active, 
preventing 
 
 
Table 2: Cancer Vaccine Trial table 
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In table 1, this was a phase ii trial, which showed effective response to these Vaccines.  
Treatment with trastusumab(Herceprin),either received the Her2-derived HLA Class I peptide 
called GP2 in combination with GM-CSF, significantly reduced the risk of regeneration and so 
the patients benefited greatly from this vaccination (Lollini et al., 2015).  
 
GVAX 
GVAX is an anticancer drug that was developed by Somatix, a gene therapy company in 
1993. This vaccine has revolutionizes the field of medicine especially in oncology. GVAX is 
made of genetically modified cancer cells which are manipulated to produce a potential cytokine 
called Granulocyte Macrophage Colony Stimulating factor, GM-CSF. This vaccine has been 
previously used as a stimulator of neutrophils and macrophages in recombinant Leucine 
production with the purpose of reducing the toxicity of intensive chemotherapy. The vaccine has 
undergone several trials that have however proved to be successful. These trials have evolved 
through phases. In phase I, there was a low response amongst the patients involved but with 
much more research, the vaccine has gained success in subsequent phases (Rowe & Beverley, 
1984) 
GVAX aids in the delivery of Tumor Associated Antigens and the subsequent secretion 
of Granulocyte Macrophage Colony Stimulating Factor through paracrine models. This secretion 
of Granulocyte Macrophage CSF leads to a cascade of events that activate the dendritic cells of 
the bone marrow. The activated dendritic cells then present the Tumor Associated Antigens that 
are expressed by the tumor. The dendritic cells have a role of preparing CD4+ and CD8+ cells that 
recruit mechanisms of tumor destruction via lysis (Singletary, 1999). The Major 
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Histocompatibility Complex of the patient in this case does not need any matching with the 
vaccine since antigens are involved in priming the T cells in relation to the tumor secretions 
(Mazanet et al., 2012). 
NeuVax 
Neuvax is mostly used in the treatment of breast cancer patients with elevated HERs 
expression and is commonly administered after surgery. This is a peptide vaccine that was 
developed with the aim of reducing the possibility of the reappearance of cancer following 
surgery or irradiation of tumor cells. The vaccine is comprised of an active form of E75 peptide 
that is isolated from the cells expressing HER2. This peptide is then combined with GM-CSF 
obtained from yeast and an adjuvant is then added. The extracellular domain HER2 acts as the 
Nona peptide source for this drug during development. Through a number of steps, the 
responsible CD8+ cells are activated after presentation of antigens to the cells. Activated CD8+ 
(CTLs) are able to identify tumor cells, neutralize them and destroy them via lysis. The cancer 
cells that are targeted are the HERs protein producing cells and metastatic precursors. The 
immune response can as well direct cytotoxic T lymphocytes to new immunogenically 
characterized peptides via inter and intergenic spreading of active epitopes. Basically NeuVax 
has been used in Prevention of Recurrence in Early Stage Positive Breast Cancers with Low to 
Intermediate HERs expression (PRESENT) trials in which the Human Leucocyte Antigen 2 and 
3 (HLA A2/A/3) also called Nelipepimut-s was being evaluated. Since this vaccine is usually 
used with an adjuvant, it is used in patients who are expressing minimum residual nature of the 
cancer (Rowe & Beverley, 1984). 
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Breast tumor antigen is important to determine the efficiency of vaccines used in treatment and 
prevention breast cancer because breast tumor antigen works as tumor rejection target. In Table2, 
Emens, 2012 summarized clinical trial of using vaccines to target HER-2 and MUC1. He 
examined the vaccines that was taking lone or low doses of cyclophosphamide and doxorubicin 
in 28 patients who had metastatic breast cancer. It was an initial clinical trial that using vaccines. 
He found that induction of induction of CD4+ T cell-dependent HER-2-specific immunity can 
measured by deleyed- type hypersensitivity (DTH) and the level of antibodies.  In addition, the 
level of CD4+ Tcells- dependent immunity was lower when use vaccine a lone. Chemotherapy 
work better with vaccine than a lone. 
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Table 3: Summary of clinical trial of using vaccines to target HER-2 and MUC1 (Adapted 
from Emens, 2012). 
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Adoptive T cell therapy for breast cancer 
 T cells are essential elements in cell mediated immunity especially for recognition of 
stray antigens in the host. They have been used in the current environment in fighting against the 
invading cancer cells through a cascade of modifications. Substantial advances have been made 
in an effort to modify the T cells by use of genetic engineering methods and the use of antibody 
recognition in Chimeric Antigen Receptors (CARs). Clinical trials have been done to evaluate 
the efficacy of genetically modified T cells in the treatment of breast cancer of which have 
proven to be very successful. The different tumor types in breast cancer have however posed a 
great challenge in the development of specific T cells for a given kind of tumor thus posing a 
great setback in this research (Libutti, 2015). 
 Adoptive T cell therapy is achieved when there is a transfusion of lymphocytes with an 
aim of treating an individual with cancer, in this case breast cancer. T cell therapy basically has 
an overall enhancement feature of antitumor immunity, augmentation of efficacy of vaccines and 
the subsequent limitation of graft-host infections. The ultimate passage of new allogenic T- cells 
into individuals with cancers has helped in the control of the growth of tumors in human 
populations especially if diagnosis is made early enough. According to Chester Southam and his 
Colleagues in 1970, leukocytes with a given ability to inhibit the implantation and growth of 
tumor cells were found in a number of patients who had advanced cancer to be used as the 
potential pol for adoptive T cell therapy (Libutti, 2015). 
 In comparison with the therapeutic cancer vaccines, the use of adoptive T cell therapy has 
not been previously practiced by most oncologists since there was no a formal approval of their 
use. Currently, the knowledge on the application of T cell therapy has opened up the dream of 
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treating breast cancer with ease. This is destined to be much more effective in with the advent of 
transfusion medicine. Emphasis is being put on Cytotoxic T lymphocytes (CTLs) and Tumor 
Infiltrating Lymphocytes (TILs) (Murray et al., 1994).  
 CTLs are obtained from Peripheral blood lymphocytes and are potential targets that have 
been used for different sets of tumors including melanoma and Breast Cancer. Tumor Infiltrating 
lymphocytes basically demand that new and fresh isolates of T cells are obtained through biopsy 
with a subsequent selection of cancer specific cells with the use of very high interleukin 2 in cell 
culture. If the host is prepared early enough with chemotherapy and then infused with the 
adoptive T cells, there is an increased response (Libutti, 2015). 
Sets of clinical models have been evaluated and they suggest that the associated transfer 
of concomitant Hematopoietic Stem Cells (HSCs) may show a greater result in promoting anti-
tumor effectiveness of the infused modified T cells. The problem scientists are currently facing 
lies on the efficiency of producing much more satisfactory specimens that can be used in 
treatment of Breast cancer as only 30-40% of Tumor Infiltrating Lymphocyte populations have 
been successfully obtained from biopsy specimens. If the current technical problems on tissue 
culture be overcome, then the whole exercise of using TILs can create a better milestone in the 
treatment of breast cancer (Murray et al., 1994). 
This kind of therapy manipulate host T cell family with an aim of destroying cancer breast 
cancer cells. The procedure involves an aseptic collection of patients’ immune cells that are 
further genetically engineered in vitro like CAR so as to identify breast tumor cells in the large 
pool of body cells. This is done through manipulating the cells to specifically recognize the types 
of chemoattractants and cytokines that are being produced by the tumor cells. These cells are 
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then purified and then re-introduced to the patient intravenously (Dudley, 2011). These T cells 
that have been modified are now capable of identifying the specific antigens that are being 
produced by the tumor cells thus can be easily destroyed. The process of T cell therapy involves 
a number of developmental stages. The sample is initially collected from the breast cells 
expressing the cancerous condition followed by hybridoma based multiplication of the tumor 
cells in the laboratory. High aseptic techniques need to be employed in the entire exercise. T 
cells are then obtained from the patients’ bloodstream and then are manipulated genetically in 
order to identify the cancer cells with specific antigens being expressed. These cells are modified 
with the incorporation of special receptors that aid in the recognition of the proteins being 
expressed on the surface of the tumor cells. These receptors are called Chimeric Antigen 
Receptors (CARs) ('Adoptive T-cell Therapy Has Clinical Activity in Metastatic Cervical 
Cancer', 2015). The adoptive T cells transfer is working by taking from patient and active them 
in vitro. These cells can activate by DCs, or by artificial T cells or by engineering T cell and then 
rejection to patient. Trying to treat HER+ breast cancer patients by transfer of autologous HER2 
specific T-cell clones and monitoring patients (Bernhard et al., 2008). 
Figure 8 shows the structure of CAR. The CAR is engineered receptor consists of two 
parts: ectodomain and endodomain. Ectodomain has a signal peptide that point protein to 
endoplasmic reticulum and linked the amino- terminal. In addition, it has the antigen recognition 
domain that is commonly be a single-chain variable fragments (scFv) derived from monoclonal 
antibodies. ScFv described from alpha and beta signal chain of naive T cell receptor (TCR) and it 
can link cytokine that lead to realization to cells which have cytokine receptor. The 
transmembrane domain that is expansion the membrane is a hydrophobic alpha helix and is 
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located in endodomain.  Connecting between the transmembrane domain and the antigen binding 
domain by a spacer region in ectodomain. Endodomain is in the last part in the receptor. Signals 
and receptors transfer to cell after antigen recognition. 
Figure 9 is a representation of engineered receptors comprised of pieces from different 
sources that were focused against both another receptor called tyrosine-protein kinase ErbB-2 
and MUCI. In figure 9A, an MUCI-specific scFv cloned from HMFG2 was coupled through an 
IgD hinge and the IgG1 Fc was connected to a human CD28+ CD3 endodomain that generate IL-
2 when co-cultivated with MUC1-expressing target cells. The CD28+ was seen to lack the scFV 
while HDF28 and HDFTr conflict the intercellular component consisted of the full or truncated 
CD28 endodomain respectively. Further, in IzI, an ErbB2-specific scFv, which was cloned from 
ICR 12 was connected through a CD8 alpha hinge and transmembrane domain to CD3  
endodomain. In 128z hinge, endomain of CD28 and transmembrane were followed by CD3  
endodomain. The arrangement MUCI/ErB2 construct was indicated. Figure 9B was a structure of 
the retroviral vector used to express IzI to gether with HDF28 or HDFTr while figure 9C three 
upper panel shows detection of MUCI-specific CARs when transduced in T-cells. They found 
the expression of ErbB2 IgG FC was not detectable in both ITH and ITHTr. Finally, figure 9D 
was a Western blotting showing how IZI expresses itself in dual targeting constructs. The rsusult 
was the mass of IZI was coordinated with efficient proteinmeadieted by retrovial vector. In 
conclution , the modified T Cells can be used as therapy for hematologic malignancies like breast 
tumors. As a result, the co-express of IZI with MUC1- spesfic HDF28 CAR can destroy various 
breast cancer monolayers even of the expression IZI was reduced (Wilkie et al., 2012).  
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Figure 10 is a graphical representation of interleukin-2 production by T-cells engineered 
to express the dual target constructs. The human T-cells that express the indicated CAR 
molecules were cultivated a night earlier with an equal number of Jurkat E6 cells or MDA-MB-
435 cells in (Figre 10A). They found the level of IL-2 decrease when ErbB2 co-express with 
MUC1. Figure 10B expresses MUC-1, ErbB2 or both antigens. The human T-cells in 10C 
express the indicated CAR molecules that were cultivated earlier with a confluent monolayer of 
the indicated mammary carcinoma cell line. In all the cases, two separate transduction with ITH 
were also tested. The supernatants were harvested and analyzed IL-2 content in triplicate. In this 
diagram, it describes a dual targeting of the ErbB2 and MUC1 in breast cancer. they demonstrate 
that T-cell activation and IL-2 production was depended onbalance between CAR expression on 
the T-cell and intensity of antigen on target cell (Wilkie et al., 2012). 
In figure 11 Bernhard et al., 2008, were monitoring the effect of transfer T cell to the 
patients by monitoring the frequency of HER2 specific T cells in both peripheral blood and bone 
marrow before and after transfer T cells. Figure 11A is in peripheral blood after 1 hours, 
measured that the frequency of HER2 specific T cells rise of CD8 T cells. After 1 day, CD8 T 
cell decreased which means is there are no reveal of the frequency of HER2 specific T cells. 
Figure 11B is in BM, also they are found rise of the frequency after 24 hours in patient with fifth 
transfer using A2/HER2. Therefore, the HER2- spesfic T cell can residence in bone marrow. 
In summary, T cells can destroy the single neoplasm cells in case of there no surrounding 
tumor cells. This sequence of events described by Bernhard et al., 2008, supports my 
hypothesis. 
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Figure 8: The structure of chimeric antigen receptor (CAR) (Adapted from wikipedia, 
2015). 
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Figure 9: Engineered receptors against both ErbB-2 and MUCI (Adapted from Wilkie et 
al., 2012). 
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Figure 10: Interleukin-2 production by T-cells engineered to express the dual target 
constructs (Adapted from Wilkie et al., 2012). 
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Figure 11: Monitoring the frequency of HER2- specific T cells in peripheral blood and 
bone morrow in patents before and after transfer adaptive T cells. A- Peripheral blood. B- 
Bone morrow (Adapted from Bernhard et al., 2008). 
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Monoclonal antibodies in targeting Breast cancer antigens 
 Monoclonal antibodies mediate cell killing by use of Antigen Dependent Cell 
Cytotoxicity (ADCC). There are approaches that have been embraced in the successful use of 
antibodies in the elimination of tumor cells including immune modification of T cell functions by 
use of ipilimumab which is monoclonal antibody can activate immune system, induction of 
ADCC by use of rituximab (chimeric monoclonal antibody) and nullification of cancer cell 
signaling by use of drugs such as centuximab (which is an epidermal growth factor receptor 
(EGFR) inhibitor used for the treatment of metastatic cancer) and trastuzumab (is a monoclonal 
antibody that interferes with the HER2/neu receptor) (Annibali et al., 1994).  
 Monoclonal antibodies have been used in treatment of breast cancer especially when the 
nature of the antigens is well known. The secreted antigens easily bind to the monoclonal 
antibodies and they prevent other antibodies from binding to the tumor in the developing cells. 
Rapid internalization of the antigen occurs in order to maximize the availability of the antigen 
binding site to the immune cells as well as the complementary proteins (Berinstein, 2009).  
 The current technologies in treatment of breast cancer largely depend on monoclonal 
antibodies targeting the specific molecules being produced by the tumor cells. HER2/neu is 
produced by tumor cells and expressed on their surface. Too much of this antigen on the surface 
of the cells facilitates rapid growth of the cells with minimum achievements of treatment. There 
are a number of drugs otherwise termed as monoclonal antibody extracts that target the antigen 
produced by the tumor cells. These include but not limited to, Trastuzumab (Herceptin), 
Pertuzumab (Perjeta), Ado-trastuzumab emtansine (Kadcyla) and Lapatinib (Tykerb) (Murray et 
al., 1994). 
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 Trastuzumab and pertuzumab are basically in vitro monoclonal antibodies that are 
administered intravenously with high immune protein specificity. Ado-trastuzumab emtansine is 
usually attached to a chemotherapeutic drug that is also administered intravenously. Of these 
drugs, only lapatinib is given as a pill. 
Role of genetically engineered monoclonal antibodies in targeting Breast cancer antigens. 
Rowe & Beverley, (1984) flag the cells, cancer cells, and make them identifiable for 
destruction. The monoclonal antibodies are specialized to identify specific receptors on the 
surface of the tumors and subsequently bind them at the at the Fc region. The flagging makes the 
cancer cells easily recognized by the other immune cells that migrate to the sites of cancer to kill 
the cells by opsonization, lysis and by use of Antigen Dependent Cell Cytotoxicity (ADCC).  
Monoclonal antibodies also act by blocking the basic signal producing processes as well 
as the receptor sites for the signals and antibodies. In the process of mAb development, scientists 
can opt to limit tumor cell growth by blocking the mechanisms that facilitate the process of 
proliferation. The genetically engineered antibodies block the major pathways such as signal 
transduction pathways, pathways that lead to initiation angiogenesis and those that allow for cell 
maturation. Since there has to be a reliable mechanism of transporting nutrients, cancer cells 
initiate the process of angiogenesis. Monoclonal antibodies that limit the process of angiogenesis 
therefore deprive the tumor cells of basic nutrients for their survival leading to cell death or 
slowed proliferation (Rowe & Beverley, 1984). 
Monoclonal antibodies are used to directly deliver drugs to the cancer cells. This process 
involves prior modification of cancer cells to carry therapeutic agents that they deliver directly to 
the cancer cells. This lies on the fact that the antibodies are capable of attaching specifically to 
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the designated breast cancer cells. Therefore, therapeutic agent is bound to the monoclonal 
antibody in vitro and the antibody marked to target specific lines of cells. The antibody is then 
introduced into the bloodstream via intravenous infusion. This antibody travels to the breast 
cancer cells where it binds with the tumor cells with subsequent delivery of the drugs. This 
happens by engulfment of the monoclonal antibodies by the cancer cells which begin to. The 
process of internalization breaks off the bound drug to release it to the environment thus causing 
cell death. The process is termed as self-suicide since the tumor cell initiates the process of its 
death. (Rodriguez-Bigas, 1992) 
Radiation particles alongside chemotherapeutic agents can also be combined with 
monoclonal antibodies and then allowed to deliver in small doses. The radiations cause death of 
the cancer cells selectively allowing the survival of adjacent cells. The monoclonal antibodies 
tagged with radiation particles are also used in the diagnosis and monitoring of the cancers using 
radioimaging techniques. Cytokines are the latest form of combination that is conjugated to the 
monoclonal antibodies. This complex is called an immunocytokine. Immunocytokines are used 
to directly deliver cytokines to the tumor cells with an aim of initiating an immune response. 
Trastuzumab, also called Herceptin, and Kadcyla (ado-trastuzumab) are the currently applied 
monoclonal antibodies (Rowe & Beverley, 1984). 
Shi et al., (2015) emphasized that neutral killer cells (NK) have significant function in 
ADCC. Also, these cells can rise infiltration of NK cells in breast cancer that bind to activity 
trastuzumab. By peripheral blood mononuclear cell (PBMC) and macrophages while 
Trastuzumab can intermediate ADCP to against HER2-expressing tumor cells. They used old 
mice that vaccinated with high HER2- expression BT474 breast cancer cells to show the 
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antitumor effectiveness of trastuzumab in infiltration of macrophages in neoplasm site. Treated 
mice with Trastuzumab and isotype IgG. Macrophages in spleen in Mice were treated with 
trastuzumab was greater than mice were treated with control isotype IgG (figure 12A). Using 
clodrosome nanoparticles to deplete macrophage in vivo. Prevent tumor development via 
trastuzumab with clodrosome (figure 12B). In (figure12 C) mice treated with trastuzumab had 
higher to kill cancer cells. This experiment demonstrated that trastuzumab had higher power to 
inhibit BT474 breast cancer cells. Also, Xenograft tumor growth and infiltration of macrophages 
in tumor site had a great significant for efficiency of trastuzumab.  
Shi et al., (2015) also studied the function of FcyRIV that expressed in macrophages in 
reach of trastuzumab-intermediate ADCC efficiency. They were using mice macrophage cell 
lines. These cells can be upregulated via combine with INF-gamma or knock down by shRNA 
lentivector system. They found that the expression of FCYRIV was higher with WT plus INF- 
gamma as showed in (figure13 A). In (figure 13B) showed the percentage of killing tumor cell 
also was elevation with WT + INF- gamma compared with WT. In addition, the activity of 
phagocytes was rising in WT plus INF- gamma in the existence of trastuzumab (figure 13C).The 
INF-gamma catalyze BBM within existence trastuzumab had a power to kill HER2 cancer cells 
and increase the percentage of phagocytes (figure13 D-F).  
Shi et al., (2015) found FCYRIV had an important function in macrophages intermediated 
ADCP and trastuzumab to destroy cancer cells.  
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Figure 12:  The antitumor efficacy of trastuzumab depends on macrophage recruitment in 
the tumor tissues. A) Macrophages (CD11b+) in the splenocytes and tumor-infiltrating cells 
of mice treated with trastuzumab or isotype control IgG with or without clodrosome 
treatment. (B)Xenograft tumor sizes of the different treatment groups. (C) The splenocytes 
(Adapted from Shi et al., 2015). 
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Figure11: The function of FCYRs that expressed in macrophages in trastuzumab-mediated 
ADCP activity (Adapted from Shi et al., 2015). 
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Checkpoint inhibitors and their contribution in Breast Cancer Therapy. 
 There are a number of checkpoint inhibitors hat have proven to be very effective in the 
treatment of a wide range of cancers such as lung cancer, lymphomas and breast cancers. 
However, breast cancers have numerous features that have a different regimen of treatment. This 
breast cancer cells may be affected by female hormones that stimulate abnormal cell growth 
(Estrogen and progesterone). (Marques et al., 2015) found that these forms of Breast Cancer that 
have been studied involve those that are associated with HER2+. These cancers come about due 
to the limitless expression of the epidermal growth factor on receptor 2 which is a cascade 
member in the growth of normal body cells. The latter kind of cancer is forms the most rampant 
kind of cancer with 2 out of 10 women with breast cancer. 
 Other breast cancers may not be caused by the above hormones and are not HER2 
negative. These are cancers collectively termed as triple negative breast cancers. These kinds of 
cancers are really active and very aggressive in terms of progression with high chances to 
metastasize to peripheral tissues. Therefore an early diagnosis of these cancers reduces the risk 
of early death due to cancer. In a study to test on the activity of the above stated checkpoint 
inhibitors, there was a recruitment of 32 cancerous individuals who had the triple negative breast 
cancer and Keytruda administered for a period of 14 days in a regular case until all the patients 
showed a response as either effective in lowering the progression or maintaining the rate of 
progression or no effect in controlling the progression. Six patients (18.5 percentage) showed a 
complete response while twenty one showed a stable condition of the disease with the rest 
having a substantial increase in the levels of progression (Libutti, 2015).  
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 Patients with HER2 cancer have also been treated with a varied number of therapies 
including the use of endocrine / HER2 targeted therapy in single forms or in a coupled 
combination in the specific individuals affected. This therapy has been known as a single or a 
lone therapy that is preferred when the patients have an asymptomatic condition of breast cancer. 
Pertuzamab is the currently preferred first line of treatment for the onset of the cancer with a 
second line of treatment being on trastuzumab. On a contrary base, as there are advances in the 
non-targeted therapy in the triple negative therapy, there are further scientific research processes 
in progress that target to investigate the novel type of surface receptors through use of 
checkpoint inhibitors with the identification of the specified targets to benefit from therapies 
based on platinum and adenosine diphosphate ribose inhibitors (Libutti, 2015). 
 On the aspect of targeting the inhibition of angiogenesis, the Eastern Cooperative 
Oncology group (ECOG) has found that if bevacicumab conjugated with paclitaxel is a random 
set of breast cancer patients, the nature of metastatic cancer is in a great fold improved. The 
process of angiogenesis uses a given set of factors known as The Fibroblast growth factor 
receptor gene (FGFR) that is a common contributor to resistance of the anti-fibroblast growth 
factor component as well offering many variations of this gene in breast cancer. Therefore in 1 
out of 10 patients with breast cancer, FGFR variations affect subsequent prognosis in the 
oncology centers. This has caused a great shift of research work on the possible means to 
develop target therapy for this growth factor. If successful, all the processes of angiogenesis by 
tumor cells are expected to be altered to in order to treat breast cancer completely (Marques et 
al., 2015). 
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Checkpoint inhibitors are not target specific and hence can work in many different tumor 
types. Check point inhibitors have a unique mechanism of action, where they target molecules 
that act as checks and balances in the regulation of immune response. Therefore, enhancing the 
cancer immune response (Hilgers et al., 1985). Mononuclear antibodies (mAbs) are known to be 
effective in blocking one or many immune checkpoints, hence, boosting the power of the 
antitumor cells. In clinical trials, anti-cytotoxic T- lymphocytes antigens 4 (CTLA -4) Mabs, has 
been tested. 
Figure 15 shows that combining the anti-CTLA-4 mAb 9H10 with local radiation therapy caused 
an extension of the survival of mice with non-immunogenic 4T1 carcinoma. Mab 9H10 is 
monoclonal antibody that can block CTLA-4. 4T1 is BALB/C mouse – derived mammary 
carcinoma cell line. They using IgG antibody as a control. Figure 15 (A) shows the growth of 
tumor volume (in mm3) over a period of 40 days after tumor inoculation under different 
treatment conditions (IgG only, 9H10 only, RT+IgG, and RT+9H10). The graph shows that 
growth of the tumor was highest in the first two treatment (IgG only and 9H10 only). However, 
tumor volume was much lower for RT + 9H10 and RT + IgG treatments. Figure 15 (B) shows 
the survival rates of mice subjected to the four treatment options after tumor inoculation. The 
highest survival rate was shown to be for mice subjected to the RT + 9H10 treatment. Survival 
was lowest for mice treated with IgG and 9H10 only. The two figures show that the combination 
of radiation therapy with 9H10 monoclonal antibodies against CTLA-4 was most effective in 
treatment of tumor. However there us limitation in this study which is the survival for five days 
more (Demaria et al., 2005). 
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 Figure 16, Demaria et al., 2005 want to make sure of the effect of the combination of RT 
with 9H10 on initial tumor grow and survive of mice. In part A, they found that the neoplasm 
degradation in two of seven mice treated with RT+ IgG. In mice treated with RT+9H10 found 
that tumor degradation in four of seven mice as shows in part B. In figure 16C there was not 
degradation of tumor in mice treated with IgG alone. In part D, they found benefit of treating 
mice with RT+9H10 in increase the degradation of tumor with long survival.  
Figure 17 shows the level of lung metastases in the lungs of mice treated with four 
treatment options: IgG only, 9H10 only, RT+IgG, and RT+9H10. The mice were sacrificed and 
the number of metastases counted. Figure17 (A) shows that the number of metastases was lowest 
for the last treatment group RT + 9H10 and highest in the control group, which was treated in 
IgG only. This implies that the combination of radiation therapy and 9H10 monoclonal 
antibodies against CTLA-4 has high therapeutic value in lung metastases in breast cancer. Figure 
167(B) shows that CD8+ T cells were depleted in the reduction of lung metastases in the 
RT+9H10 treatment while CD4+ cells were depleted in RT+IgG treatment. The figure shows 
that CD8+ T cells are required in the inhibition of lung metastases by radiation therapy and 
CTLA-4 blockade (Demaria et al., 2005).  
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 Figure 14: Therapeutic inhibitors using checkpoint process in cancer therapy treatment, 
(Adapted from Khalil et al., 2012). 
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Figure 15: Combining the anti-CTLA-4 mAb 9H10 with local radiation therapy caused an 
extension of the survival of mice with non-immunogenic 4T1 carcinoma (Adapted from 
Demaria et al., 2005). 
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Figure 16: Effects of two fractions of local RT in combination with CTLA-4 blockade on 
the primary tumor growth and survival of mice bearing the nonimmunogenic 4T1 
carcinoma (Adapted from Demaria et al., 2005). 
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Figure 17:  Level of lung metastases in the lungs of mice treated with four treatment 
options (Adapted from Demaria et al., 2005).  
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Conclusion 
Development of highly potent immunotherapy against breast cancer has been a successful 
in controlling the risks of metastasis. However, clinical evidence confirms that if the cancer is 
diagnosed early enough before advancement to complex levels, either of the discussed therapies 
can offer higher percentages of treatment. The development of monoclonal antibodies and T cell 
therapy is expected to help in complete clearance of breast cancers especially with the ability of 
monoclonal antibodies to elicit a number of mechanisms in killing cancer cells (Zhou et al., 
2007). 
Considering the current statistics regarding breast cancer immunotherapy, there is great 
correspondence to the statistical representation in the above tables. Cancer deaths are so many 
and eminent but are decreasing because of the available aspects that are regarded to induce 
objective inclination towards survival rates. In the past five years, there has been an increase in 
this survival rate to a consistent of 90 % of the cases prospected. This is described to be a 
dramatic improvement considering that the rates of cancer infections have been so much (Zhou 
et al., 2007). This is quite different as compared to the earlier years where, the infections were 
much few as compared to present times. If this consideration is expressed in terms of the stage of 
the disease, the survival rates are quite variant and can be explained using the table that is shown 
below.  
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Number  Stage  Rate  
1 1 95 % 
2 2 84 % 
3 3 60 % 
4 4 24 % 
 Table 4: Cancer survival rates against infection stages, (Adapted from immcellther.com). 
The above table shows particular aspects that will always recommend that cancer 
treatment at the early stages is so crucial and will decisively be articulated with its infection 
levels. In the past 3 decades, the level 1 survival rates were obligated at 63 % which also shows 
great improvement in the treatment of breast cancer. This is where immune therapy is so crucial 
in contribution to the current survival rates. This is why the medical positions have always 
advised that the treatment of cancer is started early and is prospected to have every indication 
intact in the sense that it will be articulated to have better performance in order to improve the 
rates from the current 24 %. Immunotherapy has had a greater hand in this improvement, 
however, with the drawbacks like having expensive inputs in the therapy articulations. Every 
inclusion is therefore important and must be accorded that the basic requirements are meant to 
reduce the risk of cancer deaths (Winchester, 1991). 
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Figure 18: Survival rates graph, (Adapted from mmcellther.com). 
The discussed aspects that aid in cancer immunotherapy are always induced to better 
performance hence. These aspects named as the prospective and justified therapy methodologies 
will include the use of vaccines, the use of check point inhibitors, the use of antibodies and the 
use of the adoptive T cell therapy. All these aspects are considerably an important aspect and are 
regarded with the objective of improving the survival rates for cancer and the positions that are 
meant to design the current statistics to further decrease in cancer cases, cancer deaths and 
increment of the survival rates of cancer and other prospects. Every consideration is therefore 
prospective towards some input in the positive influence in cancer treatment aspects. (Yee, 2013) 
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Limitations to the study and therapy 
Breast cancer is not a single disease  
Breast cancer has always been considered a multitude of diseases. Hence given the 
description of not being a single disease. There are particular biological processes that are 
involved as well as various and distinct pathways that are genetic. These pathways are also 
associated with the prognosis of the chemotherapy alongside the sensitivity that is involved. 
Ensuring that individuals who have the disease have the normal way to lead their life is quite a 
problem and is addressed with the articulated importance of less targeted agents in different 
types of breast cancer. This implies that there are numerous types of these infections that can be 
induced and lead to deaths if it is not well managed (Paoletti et al., 1993). 
Cancer immunotherapy is always a recurrent process  
This is also relented to its classification. This is because it is classified as part of the 
molecular events. This is also considered a primary challenge, especially when future drug 
development is a consideration. Every aspect in breast cancer is articulated to give a distinction 
of genes as well as the pathways that drive cancer proliferation. The identification of these 
functional pathways which are enriched for the articulated mutated genes will devolve the 
influence in subpopulations of patients that are prone to sensitivity to the agents that are 
biologically driven (Kramer et al., 1994). 
Immunotherapy is a complex process  
There is also one consideration that cancer treatment which involves immunotherapy is a 
complex process. However, we are moving to an era of stratified therapy as well as that which is 
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personalized. This is based on the precepts that there is a detailed molecular characterization of 
the patient tumor as well as its micro environment components. This will give rise to the tailored 
therapies as well as a decreased toxicity in the process. Every aspect must be ignited towards the 
numerous challenges that are meant to improve the stature of personalized immunotherapy 
protocols (Paoletti et al., 1993). 
Tumor Heterogeneity  
The processes will also include tumor heterogeneity as well as molecular evolutions as 
well as the costs. There is also potential morbidity as a factor of the biopsies, technical 
limitations in the process of therapy and the decreased effective drugs because of the genomic 
aberrations. There is also a consideration of the reimbursement and the regulatory hurdles. 
Critically, these aspects are mainly influential and have forced the improvement of the practices 
against cancer and the recurrent limitations of the therapy processes. This will influence the 
increased survival rates against the cancer prone cases (Dizdar et al., 2007). 
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Challenges in future research 
Cancer immunologists have presented various efforts towards proving the adaptive and 
innate immune cells which are meant to recognize tumor cells. This has always influenced 
injections of tumors as well as injection in the existing models of the treatment. This means that 
there is a prospective huddle in this therapy and will have the most problematic process that is 
capable of better performance and other related aspects. There is a rationale of study in the future 
in this argument in the sense that it is articulated towards various aspects of ever changing stages 
of the immunotherapy aspects. The strategies are influenced by the most difficult facial situations 
that are anti-tumor immune responses. We therefore focus on changing aspects in this process of 
therapy which will always require new studies as well. In addition, using older mice in trail is the 
best because the old women are more susceptible to breast cancer.  
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